Claims Against Generic Manufacturer are Not Preempted, Court Affirms



DOCUMENTS
  • Opinion


NEW ORLEANS - Generic drug manufacturers can strengthen their warning labels after the initial approval process without violating FDA rules, the 5th Circuit U.S. Court of Appeals has affirmed, rejecting Actavis Inc.'s argument that claims against it are preempted by federal law. Demahy v. Actavis Inc., No. 08-31204 (5th Cir.).

On Jan. 8, the appellate court, led by Judge Patrick E. Higginbotham, ruled that federal regulations did not preempt a consumer's state law failure-to-warn claims based on alleged inadequacy of generic drug labels.

Julie Demahy was prescribed Reglan to treat her gastroesophageal reflux and for the next four years, …






UPCOMING CONFERENCES




HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS